Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 292

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 292
---
 diligence review. Samsung Biologics Acquisition of Biogen’s Stake in Samsung Bioepis (2022): Samsung Biologics acquired Biogen’s entire stake in Samsung Bioepis for approximately $2.3 billion, making it a wholly -ownedsubsidiary. This move was aimed at strengthening Samsung Biologics’ position in the biosimilars market and expanding its global footprint. SK Group Acquisition of AMPAC Fine Chemicals (2018): SK Holdings, part of the SK Group, acquired AMPAC Fine Chemicals, a U.S. -basedcontract development and manufacturing organization (CDMO). This acquisition was valued at around $700 million and aimed to bolster SK’s capabilities in pharmaceutical manufacturing. LG Chem Acquisition of AVEO Pharmaceuticals (2023): LG Chem acquired AVEO Pharmaceuticals, a U.S. -basedoncology -focusedbiopharmaceutical company, for approximately $566 million. This acquisition aimed to enhance LG Chem’s oncology pipeline and strengthen its presence in the global biopharmaceutical market. Celltrion Acquisition of Plant in the UK from Hospira (2014): Celltrion acquired a biosimilar production facility in the UK from Hospira (now a subsidiary of Pfizer). This acquisition was part of Celltrion’s strategy to increase its manufacturing capacity and expand its presence in the European market. GC Pharma Acquisition of a Plasma Fractionation Plant from Biotest (2019): GC Pharma acquired a plasma fractionation plant in Germany from Biotest. This deal was aimed at expanding GC Pharma’s production capacity for plasma -derivedtherapies and enhancing its global supply chain. Hanmi Pharmaceutical Acquisition of Spectrum Pharmaceuticals’ Rights to Rolontis (2019): Hanmi Pharmaceutical acquired the global rights (excluding China) to Rolontis, a long -actinggranulocyte colony -stimulatingfactor, from Spectrum Pharmaceuticals. This deal, worth $160 million, included an upfront payment and milestones. Lotte Group Acquisition of Bristol -MyersSquibb’s Manufacturing Facility in Ireland (2021): Lotte Biologics, a subsidiary of Lotte Group, acquired Bristol -MyersSquibb’s biologics manufacturing facility in Swords, Ireland. The acquisition, valued at approximately $160 million, was aimed at entering the biologics CDMO business. 3)Research and Development (R&D) •Establishing R&D Centers: Large Korean companies are setting up dedicated R&D centers focusing on biotechnology and healthcare. These centers aim to drive